XOMA Corp
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 13
- Market Cap
- $344.9M
- Introduction
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
XOMA's (XOMA) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reiterated a buy rating on XOMA with a $117.00 target, while StockNews.com upgraded XOMA from 'sell' to 'hold'. XOMA's stock opened at $29.51 with a market cap of $345.27 million. The company reported a quarterly loss of $0.28 EPS, missing estimates by $0.02. Institutional investors, including BNP Paribas and Price T Rowe, increased their stakes in XOMA.
Hypoglycemia Global Clinical Trials Review 2024
The "Hypoglycemia - Global Clinical Trials Review, 2024" report offers an overview of global hypoglycemia clinical trials, detailing trial numbers, enrollment, and trends by region, country, phase, status, and sponsor type. It highlights key companies and drugs involved, aiding in strategic investment and identifying clinical trial opportunities.
Type 1 Diabetes (T1D) Market: Global Industry Analysis
The global Type 1 Diabetes (T1D) market is projected to grow at a CAGR of 17.2%, reaching US$ 38.63 Bn by 2029. Driven by increased awareness, technological advancements in insulin delivery, and government initiatives, the market faces challenges like high costs and biosimilars. North America leads, with APAC expected to grow significantly.
Type 1 Diabetes Market Size is Estimated to Reach US$ 13.64
The Type 1 Diabetes Market, valued at US$ 7.59 billion in 2022, is projected to grow to US$ 13.64 billion by 2030, with a CAGR of 7.6%. Treatment involves external insulin support, primarily through parenteral administration. The market is competitive, with major players investing in R&D for effective treatments. Key segments include devices, end-users, and products.
© Copyright 2025. All Rights Reserved by MedPath